Table 1.

Characteristics of subjects entered into the Astra Zeneca sponsored clinical study D1330N00013 whose blood samples where utilised in the present study

Patient	Age (Median)	Performance status (Who)	Stage	Grade (Gleason)	Baseline PSA (Median, ng/ml)
Group I	71	Normal-Restricted Activity	Localised	Intermediate (5–7)	7.0
Group II	74	Normal-Restricted Activity	Locally Advanced/ Metastatic	High (8–10)	23.2